These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 35947585)

  • 1. In vitro evaluation of global coagulation potentials in the co-presence of plasma-derived factors Viia/X products (Byclot
    Nakajima Y; Takami E; Nakano H; Nogami K
    Haemophilia; 2022 Sep; 28(5):e149-e152. PubMed ID: 35947585
    [No Abstract]   [Full Text] [Related]  

  • 2. Low dose emicizumab prophylaxis in haemophilia a patients: A pilot study from India.
    Bansal S; Donners AAMT; Fischer K; Kshirsagar S; Rangarajan S; Phadke V; Mhatre S; Sontate B; Silva M; Ansari S; Shetty S
    Haemophilia; 2023 May; 29(3):931-934. PubMed ID: 37029771
    [No Abstract]   [Full Text] [Related]  

  • 3. Switching to emicizumab: A prospective surveillance study in haemophilia A subjects with inhibitors.
    Dubé E; Merlen C; Bonnefoy A; Pilon J; Zourikian N; Gauthier J; St-Louis J; Rivard GÉ
    Haemophilia; 2023 Jan; 29(1):348-351. PubMed ID: 36315386
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of emicizumab on APTT, one-stage and chromogenic assays of factor VIII in artificially spiked plasma and in samples from haemophilia A patients with inhibitors.
    Bowyer A; Kitchen S; Maclean R
    Haemophilia; 2020 May; 26(3):536-542. PubMed ID: 32249990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Laboratory coagulation tests and emicizumab treatment A United Kingdom Haemophilia Centre Doctors' Organisation guideline.
    Jenkins PV; Bowyer A; Burgess C; Gray E; Kitchen S; Murphy P; Platton S; Riddell A; Chowdary P; Lester W
    Haemophilia; 2020 Jan; 26(1):151-155. PubMed ID: 31859415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A.
    Shima M; Hanabusa H; Taki M; Matsushita T; Sato T; Fukutake K; Fukazawa N; Yoneyama K; Yoshida H; Nogami K
    N Engl J Med; 2016 May; 374(21):2044-53. PubMed ID: 27223146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emicizumab assays evaluations with four different reagents in severe haemophilia A patients: Concentration from baseline to maintenance therapy.
    Launois A; De Raucourt E; Martin-Toutain I; Samdjee F; Le Dore S; Ferre E; Flaujac C
    Haemophilia; 2023 Jan; 29(1):374-376. PubMed ID: 36446748
    [No Abstract]   [Full Text] [Related]  

  • 8. Major surgery management in patients with haemophilia A and inhibitors on emicizumab prophylaxis without global coagulation monitoring.
    Biron-Andreani C; Diaz-Cau I; Ranc A; Navarro R; Leonardi C; Dischino M; Guy R; Theron A; Garcia-Gournay C; Santagostino E; Schved JF
    Br J Haematol; 2020 May; 189(3):e100-e103. PubMed ID: 32087028
    [No Abstract]   [Full Text] [Related]  

  • 9. Emicizumab for the treatment of haemophilia A: a narrative review.
    Franchini M; Marano G; Pati I; Candura F; Profili S; Veropalumbo E; Masiello F; Catalano L; Piccinini V; Vaglio S; Pupella S; Liumbruno GM
    Blood Transfus; 2019 May; 17(3):223-228. PubMed ID: 31246563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase IV, multicentre, open-label study of emicizumab prophylaxis in people with haemophilia A with or without FVIII inhibitors undergoing minor surgical procedures.
    Escobar M; Dunn A; Quon D; Trzaskoma B; Lee L; Ko RH; Carpenter SL
    Haemophilia; 2022 Jul; 28(4):e105-e108. PubMed ID: 35510949
    [No Abstract]   [Full Text] [Related]  

  • 11. Prophylaxis with emicizumab in children under 12 years old with haemophilia A without inhibitors in Uruguay: National experience.
    Lemos F; Petraccia C; Fraga ML; Casuriaga AL; Lutz S; Gómez R; Giachetto G; Boggia B
    Haemophilia; 2024 Jul; 30(4):1077-1079. PubMed ID: 38684449
    [No Abstract]   [Full Text] [Related]  

  • 12. Emicizumab-kxwh: First Global Approval.
    Scott LJ; Kim ES
    Drugs; 2018 Feb; 78(2):269-274. PubMed ID: 29357074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A modified thrombin generation assay to evaluate the plasma coagulation potential in the presence of emicizumab, the bispecific antibody to factors IXa/X.
    Ogiwara K; Nogami K; Matsumoto N; Noguchi-Sasaki M; Hirata M; Soeda T; Shima M
    Int J Hematol; 2020 Nov; 112(5):621-630. PubMed ID: 32748217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapidly loading emicizumab without immunosuppression in acquired haemophilia.
    Ragni MV
    Lancet Haematol; 2023 Nov; 10(11):e870-e871. PubMed ID: 37858327
    [No Abstract]   [Full Text] [Related]  

  • 15. Use of global assays to monitor emicizumab prophylactic therapy in patients with haemophilia A with inhibitors.
    Brophy DF; Martin EJ; Kuhn J
    Haemophilia; 2019 Mar; 25(2):e121-e123. PubMed ID: 30748061
    [No Abstract]   [Full Text] [Related]  

  • 16. Paradigm shifts in haemophilia A therapy with emicizumab prophylaxis in Asia.
    Sosothikul D; Moonla C
    Ann Acad Med Singap; 2023 Nov; 52(11):556-558. PubMed ID: 38920143
    [No Abstract]   [Full Text] [Related]  

  • 17. Emicizumab Prophylaxis in Hemophilia A with Inhibitors.
    Oldenburg J; Mahlangu JN; Kim B; Schmitt C; Callaghan MU; Young G; Santagostino E; Kruse-Jarres R; Negrier C; Kessler C; Valente N; Asikanius E; Levy GG; Windyga J; Shima M
    N Engl J Med; 2017 Aug; 377(9):809-818. PubMed ID: 28691557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferences by factor VIII and lupus anticoagulant in the modified one-stage assay for emicizumab.
    Habay C; Auditeau C; Blandinières A; Bentounes NK; Lavenu-Bombled C; Harroche A; Bally C; Frenzel L; Borgel D; Lasne D
    Haemophilia; 2023 Nov; 29(6):1661-1664. PubMed ID: 37751318
    [No Abstract]   [Full Text] [Related]  

  • 19. Safety first: Tracking adverse events associated with new therapies for people with hemophilia.
    Recht M
    J Thromb Haemost; 2021 Jan; 19 Suppl 1():3-5. PubMed ID: 33331044
    [No Abstract]   [Full Text] [Related]  

  • 20. Development of VIII inhibitors beyond 50 exposure days to rFVIII during prophylactic emicizumab therapy.
    Mitani Y; Honda M; Mizushima Y; Mori M; Fukuoka K; Oshima K; Arakawa Y; Taira K; Tanami Y; Koh K
    Haemophilia; 2023 Nov; 29(6):1653-1655. PubMed ID: 37707369
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.